Mounjaro, Zepbound shortage eases
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
FDA says shortage of popular diabetes, weight-loss drugs resolved
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — has been resolved.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly’s Tirzepatide No Longer on FDA Drug Shortage List
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market share in incretin products as manufacturing continues to expand, while noting the drugmaker could start to benefit heading into third quarter earnings.
Ozempic, Other Diabetes-Weight Loss Drugs Linked to 162 Deaths, According to FDA Data
Ozempic and other diabetes-weight loss drugs have been linked to at least 162 deaths and 10,000 cases involving “serious” injuries since
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
US FDA says Lilly's weight-loss drug no longer in shortage
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday. Mounjaro has been on the FDA's shortage list since late 2022,
Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. That’s Bad for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
FiercePharma7h
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
FDA makes end of Zepbound, Mounjaro shortage official
Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...
'King Kong' of weight loss jabs Mounjaro to be rolled out on the NHS to tackle obesity
NHS says a quarter of a million people will be offered tirzepatide - brand name Mounjaro - after trials showed it helped obese participants lose a fifth of their body weight ...
Zepbound is no longer in shortage. Hims & Hers stock took a hit because of it
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...